In silico identification and biological evaluation of newly synthetic hinokiflavone derivatives as multi-kinase inhibitors with preferential Aurora A activity for ovarian cancer therapy.
Aurora A kinase overexpression has been implicated in ovarian cancer progression, highlighting its potential as a therapeutic target. In this study, we performed structure-based virtual screening of our proprietary natural product database, identifying hinokiflavone (HNK) as a novel Aurora A inhibitor. Kinase profiling...